Éva Remenár

TL;DR: A randomised, phase 3 study of participants with untreated locally incurable recurrent or metastatic HNSCC done at 200 sites in 37 countries finds that pembrolizumab alone improved overall survival and progression-free survival and cetuximab with chemotherapy improved Overall survival in the total population.

TL;DR: Tumor EGFR copy number is not a predictive biomarker for the efficacy of cetuximab plus platinum/5-FU as first-line therapy for patients with R/M SCCHN.

TL;DR: In patients with R/M HNSCC and low or no PD-L1 tumor cell expression, all 3 regimens exhibited a manageable toxicity profile and Durvalumab and durvalumAB + tremelimumab resulted in clinical benefit, with minimal observed difference between the two.

TL;DR: The results of this multicentre, randomised, double-blind, placebo-controlled phase 2 study suggest that buparlisib in combination with an paclitaxel could be effective second-line treatment for patients with platinum-preted recurrent or metastatic squamous cell carcinoma of the head and neck.

TL;DR: Durvalumab demonstrated antitumour activity with acceptable safety in PD-L1-high patients with R/M HNSCC, supporting its ongoing evaluation in phase III trials in first- and second-line settings.